Tuesday, May 30, 2023

561.316.3330

Biotechnology News Magazine

Airway Therapeutics Completes Dose Escalation in Phase 1b Trial of Zelpultide Alfa (AT-100) for Very Preterm Infants at Risk for Bronchopulmonary Dysplasia

DSMC finds no safety concerns, allows use of highest dose for continued administration. Interim analysis of the trial expected in next month. Company opens Spanish subsidiary to lead EU clinical trials

Latest Posts

Roche introduces navify® Algorithm Suite, a digital library of medical algorithms that enhances clinical decision-making to optimise patient care

At the global HIMSS1 Conference, Roche showcases navify Algorithm Suite, a single platform offering clinicians access to medical algorithms generating insights to help improve care decisions.

PathO3Gen Solutions UVZone® Proven 99.9993% Effective Against Candida Auris: Shoes and Floors in Healthcare Facilities Should Be Addressed as Outbreak Continues

PathO3Gen Solutions’ multi-patented UVZone Shoe Sanitizing Stations, when placed in high-traffic and high-risk areas, enhance healthcare facility infection control measures, and may improve overall hospital biosafety.

Pharming announces the first commercial shipments of Joenja® (leniolisib) to patients in the U.S.

Under the terms of Pharming's 2019 exclusive license agreement with Novartis for leniolisib, the corresponding first commercial sale of Joenja® triggers a $10 million milestone payment by Pharming to Novartis.

MGCLF – MGC Pharma’s CannEpil® Now Accessible to UK Patients on Named Patient Request Basis

European pharmaceutical company offers its investigational medicinal product to a wide range of specialist medical practitioners in the United Kingdom Epidiolex's Success Highlights Potential for MGC Pharma's CannEpil®.

Airway Therapeutics, Inc., a biopharmaceutical company developing a new class of biologics to break the cycle of injury and inflammation for patients with respiratory and inflammatory diseases, announced today it successfully finished the dose escalation portion of its Phase 1b trial of zelpultide alfa for preventive use in very preterm infants at risk for bronchopulmonary dysplasia (BPD).

The Phase 1b trial is being conducted in the U.S. and Spain. Airway has established a subsidiary, Airway Spain SL, to lead the Phase 1b trial and subsequent clinical trials across the E.U.

“This is a significant milestone in our efforts to protect these infants from suffering severe BPD. The very favorable safety profile is particularly important in these extremely vulnerable preterm neonates,” said Airway CEO and Chief Medical Officer Marc Salzberg, M.D.

“The DSMC confirmed the excellent safety profile of zelpultide alfa following completion of the third cohort of infants who received the highest dose. This dose is being used in a fourth and final cohort which now also includes infants born at 23 – 24 weeks, the earliest gestational age in our study.”

As many as 2.5 million very preterm infants globally are at risk of developing BPD from lung damage caused by mechanical ventilation and oxygen support. Babies who develop BPD can suffer lifelong complications such as asthma and pneumonia as well as growth and developmental problems.

Zelpultide alfa is a recombinant version of the endogenous human SP-D, a protein essential to the lung’s immune defense in reducing inflammation and infection while modulating immune responses. The biologic is administered intratracheally during mechanical ventilation.

The Phase 1b trial is a randomized, blinded, air-sham controlled study to establish the safety and tolerability of zelpultide alfa. Interim analysis of the data is expected in early Q2 2023. The FDA and European Medicines Agency have granted orphan drug status to zelpultide alfa.

Latest Posts

Learn More

spot_img

Subscribe

spot_img

Our Sister Publication

Medical Device News Magazine